PURPOSE: To evaluate the effectiveness of concurrent chemoradiation therapy (CCRT) with 40  Gy followed by consolidation chemotherapy for localized extranodal natural killer (NK)/ @entity784 (ENKTL), nasal type. METHODS AND MATERIALS: From August 2004 to August 2012, 62 @entity1 with newly diagnosed stage IE to IIE ENKTL underwent CCRT followed by consolidation chemotherapy. The median @entity138 dose was 40  Gy. @entity900 , 30  mg/m(2), was administered weekly during the @entity138 course. Responders to CCRT were encouraged to undergo consolidation chemotherapy. Three different consolidation chemotherapy regimens were used consecutively: VIPD ( @entity2879 , @entity1260 , @entity900 , and @entity619 ); VIDL ( @entity2879 , @entity1260 , and @entity619 followed by intramuscular injection of @entity4445 ); and MIDLE ( @entity1499 , @entity2879 , @entity1260 , @entity9614 , and @entity4445 ). RESULTS: The median follow-up period was 49  months (range 8-112). After completion of CCRT, 56 @entity1 (90.3%) had a complete response, 4 (6.4%) had a partial response, 1 (1.6%) had stable disease, and 1 @entity1 (1.6%) had @entity74 ( @entity74 ). Consolidation chemotherapy was recommended to 61 @entity1 , after excluding the @entity1 with @entity74 , but was actually delivered to 58. Of these 58 @entity1 , 56 (96.5%) had a complete response and 2 (3.5%) had @entity74 . During the follow-up period, 17 @entity1 (including 3 with @entity74 ) experienced progression. The median interval to progression was 11  months (range 1-61). Local failure developed in 6 @entity1 , of whom, 2 had developed progression outside the @entity138 field. For all @entity1 , the 3-year overall survival, progression-free survival, and local control rates were 83.1%, 77.1%, and 92.4%, respectively. Grade >= 3 nonhematologic @entity137 developed in only 3 @entity1 (4.8%). CONCLUSIONS: Excellent clinical outcomes were achieved using CCRT with 40  Gy followed by consolidation chemotherapy. Additional investigation, however, is warranted to confirm our findings.

Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/ XXXX , Nasal Type.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity138 :: ('MESH:C563738', 'Disease') :: ['RT'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin', 'Cisplatin'] @entity784 :: ('MESH:D016399', 'Disease') :: ['T-cell lymphoma'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity4445 :: ('80150', 'Gene') :: ['l-asparaginase'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity74 :: ('MESH:D030342', 'Disease') :: ['PD', 'progressive disease'] @entity1260 :: ('MESH:D007069', 'Chemical') :: ['ifosfamide'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity9614 :: ('MESH:D015080', 'Chemical') :: ['mesna']
@entity784 :: (MESH:D016399,Disease) :: ['T-Cell Lymphoma']
